MITO - Stealth BioTherapeutics Corp

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
11.00
-0.12 (-1.08%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close11.12
Open11.00
Bid0.00 x 1100
Ask0.00 x 900
Day's Range11.00 - 11.00
52 Week Range11.00 - 20.99
Volume1,825
Avg. Volume5,275
Market Cap378.858M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-13.49
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est27.60
Trade prices are not sourced from all markets
  • Stealth BioTherapeutics to Host KOL Breakfast Symposium on the Potential of Elamipretide in Orphan Mitochondrial Disorders
    PR Newswire16 days ago

    Stealth BioTherapeutics to Host KOL Breakfast Symposium on the Potential of Elamipretide in Orphan Mitochondrial Disorders

    BOSTON, July 2, 2019 /PRNewswire/ -- Stealth BioTherapeutics (MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that the Company will host a key opinion leader (KOL) breakfast symposium on Thursday, July 11, 2019 at 8:00 a.m. ET in New York City. The event will focus on the potential of the Company's lead candidate, elamipretide, in Primary Mitochondrial Myopathy and Barth's Syndrome and showcase data from its ongoing clinical programs, including data which was recently presented at Mitochondrial Medicine Symposium 2019, posters from which are now available on the Company's website.

  • Celgene (CELG) Hits 52-Week High, Can the Run Continue?
    Zackslast month

    Celgene (CELG) Hits 52-Week High, Can the Run Continue?

    Celgene (CELG) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

  • PR Newswire2 months ago

    Stealth Biotherapeutics to Present at Upcoming Investor Conferences

    BOSTON , May 30, 2019 /PRNewswire/ -- Stealth BioTherapeutics Corp (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies ...

  • Stealth BioTherapeutics Reports First Quarter 2019 Financial Results And Recent Business Highlights
    PR Newswire2 months ago

    Stealth BioTherapeutics Reports First Quarter 2019 Financial Results And Recent Business Highlights

    BOSTON , May 15, 2019 /PRNewswire/ --  Stealth BioTherapeutics Corp (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies ...

  • Stealth BioTherapeutics to Present at UBS Global Healthcare Conference
    PR Newswire2 months ago

    Stealth BioTherapeutics to Present at UBS Global Healthcare Conference

    BOSTON , May 14, 2019 /PRNewswire/ -- Stealth BioTherapeutics (NASDAQ:MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases ...

  • In slow year for life science IPOs, this venture firm is making big money
    American City Business Journals2 months ago

    In slow year for life science IPOs, this venture firm is making big money

    The slowing of Massachusetts biotech and medical device companies’ stock market launches has left most venture creation firms without exit opportunities, except for one.

  • Stealth BioTherapeutics Announces Positive Results for Elamipretide in Ophthalmic Conditions
    PR Newswire3 months ago

    Stealth BioTherapeutics Announces Positive Results for Elamipretide in Ophthalmic Conditions

    BOSTON, April 30, 2019 /PRNewswire/ -- Stealth BioTherapeutics (MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, recently presented positive results from its ophthalmic programs in dry age-related macular degeneration (AMD) and Leber's hereditary optic neuropathy (LHON). The data, which were presented at the Association for Research in Vision and Ophthalmology (ARVO) 2019 Annual Meeting, being held April 28 – May 2 in Vancouver, British Columbia, demonstrated significant improvements in visual function following treatment with elamipretide, an investigational drug, in its ReCLAIM study of patients with dry AMD and in the open-label portion of its ReSIGHT study of patients with LHON.

  • Stealth BioTherapeutics Completes Enrollment of Pivotal Study in Primary Mitochondrial Myopathy
    PR Newswire3 months ago

    Stealth BioTherapeutics Completes Enrollment of Pivotal Study in Primary Mitochondrial Myopathy

    "The debilitating fatigue and muscle weakness due to primary mitochondrial myopathy often has a negative impact on the quality of life of affected patients," said Dr. Michio Hirano, professor of neurology at Columbia University Medical Center in New York, who enrolled the most patients across the 28 sites involved in the trial. Approximately 40,000 individuals in the U.S. have been diagnosed with PMM, a rare primary mitochondrial disease. There are currently no therapies approved by the U.S. Food and Drug Administration (FDA) for the treatment of PMM.

  • Stealth BioTherapeutics Announces Positive Results for Elamipretide in Barth Syndrome Open-Label Extension Trial
    PR Newswire3 months ago

    Stealth BioTherapeutics Announces Positive Results for Elamipretide in Barth Syndrome Open-Label Extension Trial

    BOSTON, April 16, 2019 /PRNewswire/ -- Stealth BioTherapeutics (MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced positive results from the open-label extension of the Phase 2/3 TAZPOWER study of elamipretide, an investigational drug, in patients with genetically confirmed Barth syndrome. Barth syndrome is an ultra-rare mitochondrial disease in which reduced levels of the mitochondrial phospholipid cardiolipin are associated with skeletal muscle weakness, debilitating fatigue, cardiac abnormalities, recurrent infections, delayed growth and reduced life expectancy.

  • Stealth BioTherapeutics Reports Fiscal Year 2018 Financial Results and Recent Business Highlights
    PR Newswire3 months ago

    Stealth BioTherapeutics Reports Fiscal Year 2018 Financial Results and Recent Business Highlights

    Completed initial public offering with gross proceeds of $85.1 million Dosed first patient in Phase 2b study of elamipretide in patients with dry AMD with geographic atrophy FDA interactions on Barth syndrome ...

  • Stealth BioTherapeutics to Present at H.C. Wainwright Global Life Sciences Conference
    PR Newswire4 months ago

    Stealth BioTherapeutics to Present at H.C. Wainwright Global Life Sciences Conference

    BOSTON , April 2, 2019 /PRNewswire/ -- Stealth BioTherapeutics (NASDAQ:MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases ...

  • Stealth BioTherapeutics Announces Dosing Of First Patient In Phase 2 Study Of Elamipretide For The Treatment Of Dry AMD
    PR Newswire4 months ago

    Stealth BioTherapeutics Announces Dosing Of First Patient In Phase 2 Study Of Elamipretide For The Treatment Of Dry AMD

    BOSTON, March 28, 2019 /PRNewswire/ -- Stealth BioTherapeutics (MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that it has dosed the first patient in ReCLAIM-2, a Phase 2 study of elamipretide in patients with dry age-related macular degeneration (AMD) with geographic atrophy.

  • Benzinga4 months ago

    BMO Bullish On 'Blockbuster Potential' Of Stealth BioTherapeutics' Lead Candidate

    Stealth BioTherapeutics Corp (NASDAQ: MITO )'s lead drug elamipretide has “blockbuster potential” in primary mitochondrial dysfunction, or PMM, according to BMO Capital Markets. The Analyst BMO Capital ...

  • Stealth BioTherapeutics Announces Partial Exercise and Closing of Over-Allotment Option
    PR Newswire4 months ago

    Stealth BioTherapeutics Announces Partial Exercise and Closing of Over-Allotment Option

    BOSTON, March 4, 2019 /PRNewswire/ -- Stealth BioTherapeutics (MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that it has issued an additional 588,232 American Depositary Shares ("ADSs") at the public offering price of $12.00 per ADS, resulting in additional gross proceeds of approximately $7.1 million, pursuant to the exercise in part of the underwriters' over-allotment option in connection with Stealth's previously announced initial public offering of ADSs. After giving effect to the partial exercise of the over-allotment option, the total number of ADSs sold by Stealth in the initial public offering was 7,088,232 ADSs and total gross proceeds, before deducting underwriting discounts and commissions and other offering expenses payable by Stealth, were approximately $85.1 million.

  • Benzinga5 months ago

    IPO Outlook For The Week: Biotechs And Another Virgin Group Addition

    For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . IPO dates below are expected but not confirmed. Anchiano Therapeutics Ltd. (ANCN) will issue 2.4 million shares at $14.55 ...